Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Lipomatous hypertrophy of the interatrial septum

Lipomatous hypertrophy of the interatrial septum is a benign condition characterized by an accumulation of nonencapsulated adipose tissue in the septal region between the two atria, typically sparing the fossa ovalis. It is also referred to by the acronyms LHIS or LASH in the international literature. It is a pseudotumoral lesion, distinct from a true lipoma: its clinical importance lies chiefly in the possibility of mistaking it for a neoplasm, its association with rhythm disturbances and, less commonly, its compressive effects on venous and atrial structures.
Recognition of the anatomical distribution and adipose composition generally allows a noninvasive diagnosis. In most patients, the finding calls for appropriate assessment and conservative management; interventions are reserved for particular circumstances. Diagnostic accuracy therefore has direct therapeutic value because it can avoid an unnecessary biopsy or operation.

The condition is seen mainly in older age and is associated with greater body and epicardial adiposity. Its frequency depends on the method used and the population examined. In the prospective study by Heyer and colleagues, 28 cases were identified among 1,292 patients undergoing chest CT, representing 2.2%; the mean age of affected patients was approximately 72 years. This is a detection frequency in an imaging cohort, not an annual incidence or an estimate to be indiscriminately applied to the general population.
The increased use of CT, MRI and procedures requiring septal assessment has made incidental discovery more common. A large finding may have been present for a long time without causing symptoms, while its dimensions and appearance may vary with the imaging plane. The initial question is therefore whether it represents the typical lipomatous configuration or a different mass in the same region.

Etiology, anatomy and pathogenesis

The accumulation develops primarily in tissues surrounding the fossa ovalis, a relatively thin anatomical region, and involves the superior and inferior portions of the interatrial region. Some of what is called the septum on imaging actually consists of folds of atrial walls with adipose tissue interposed. This arrangement helps explain the central sparing and bilobed appearance, often described as dumbbell-shaped or hourglass-shaped. Distribution is more significant than the mere presence of fat, which may be normal in other cardiac structures.

The pathogenesis has not been fully established. Age and adiposity are repeatedly observed associations, but do not by themselves explain the extent of accumulation in every individual. Expansion of local adipose tissue has been proposed, with mature adipocytes and variable amounts of brown fat. The term hypertrophy is traditionally used to describe the finding and does not imply that increased thickness is primarily due to cardiac muscle cells.
The condition must not be equated with hypertrophic cardiomyopathy or interpreted as a direct consequence of increased atrial pressure. Its relationship with obesity and metabolic syndrome also requires caution: these factors may coexist and contribute to overall cardiovascular risk without making every increase in cardiac fat a pathological mass requiring treatment.

Histologically, adipocytes are seen interspersed among residual myocardial bundles without being enclosed in a capsule, together with variable amounts of fibrous tissue. The presence of brown fat contributes to the lesion's possible metabolic activity. Entrapped muscle cells may appear enlarged and the composition may be heterogeneous, but the significance of the finding depends on the overall architecture. Pathological series, including that by Bois and colleagues on cardiac lipomatous masses, emphasize the need to distinguish these accumulations from circumscribed adipose neoplasms.

The lack of a capsule differentiates the lesion from a cardiac lipoma, although this single feature is not sufficient for every complex diagnosis. The appearance must be interpreted together with the location and preservation of the fossa ovalis. Lobulated growth of fat in the interatrial region may be pronounced without behaving like a sarcoma. Solid nodular components, destructive invasion or discordant tissue characteristics instead require reassessment of whether the original designation is correct.

Pathophysiology and significance of the association with arrhythmias

Most accumulations do not obstruct flow or alter cardiac function to a clinically relevant degree. The thickening remains part of the wall, with a generally stable surface and without the mobility typical of pedunculated masses. This explains why the main risk is not the detachment of fragments: lipomatous hypertrophy is not regarded as a common source of tumor embolism. An embolic event requires investigation of relevant causes, including atrial fibrillation when documented.

The association with atrial arrhythmias has been described in clinical and pathological series. Fat interposed between muscle bundles may alter conduction and create local heterogeneity; distortion of atrial architecture may also contribute. These are plausible mechanisms, but they do not establish by themselves that the accumulation caused an arrhythmia in a particular patient. Age, obesity, hypertension, sleep apnea and other heart diseases are common in the same population and are potential confounding factors.
Atrial fibrillation, flutter or supraventricular tachycardias must therefore be characterized and treated according to their own clinical significance. The mere coexistence of the mass does not justify resection, nor does it predict that surgery will normalize the rhythm. Conduction disturbances have been described more rarely, particularly when the extension involves functionally important regions.

Very extensive forms may cause compression of the superior vena cava or right atrium, reducing venous return or the space available for filling. Significance depends on the degree of narrowing and its functional consequences, not on septal thickness alone. Anatomical contact without changes in lumen caliber or flow does not amount to obstruction. When obstruction is real, increased upstream pressure can produce signs of congestion in the affected territory and change treatment indications.

Clinical manifestations, medical history and physical examination

The most common presentation is an incidental finding during echocardiography, chest CT, MRI or an oncological investigation. The medical history establishes the original indication for imaging and checks for potentially related complaints. Palpitations, exercise intolerance, episodes of presyncope or dyspnea may warrant further investigation, but remain nonspecific. A history of arrhythmias, underlying heart disease, weight changes and treatments, as well as earlier studies showing the same configuration, is useful.

In patients with palpitations, frequency, duration, regularity and any association with syncope or pain should be established. Electrocardiographic documentation is needed to distinguish extrasystoles, atrial fibrillation and other tachycardias. If facial or neck swelling, a sensation of cranial fullness or superficial venous collaterals appear, assessment must consider possible vena caval obstruction, as well as all other causes of this presentation. In patients with cancer, a lipomatous explanation for an abnormality in the atrial region does not justify ignoring concurrent venous thrombosis or mediastinal masses.

On physical examination, rhythm, blood pressure, perfusion and signs of congestion are assessed. Atrial fibrillation may cause an irregular pulse; a conduction disorder may cause bradycardia. Examination looks for signs of superior venous obstruction when suspected and evaluates other conditions that could explain dyspnea and functional limitation. There is no characteristic murmur of the lesion, and a normal cardiac examination is entirely compatible with an anatomically substantial accumulation.
The clinical objective is to distinguish three situations: a finding without demonstrable effects, a condition coexisting with an arrhythmia requiring independent management, and a rare truly obstructive form. These possibilities entail different approaches despite sharing similar adipose morphology.

Diagnosis by imaging and main differential diagnoses

Transthoracic echocardiography may show hyperechoic thickening of the interatrial region, often most readily seen in subcostal views. Preservation of the fossa ovalis and thickening of the surrounding portions suggest the diagnosis. Visualization may be limited by body habitus or septal orientation, risking the misinterpretation of one part of the deposit as an isolated mass. Imaging in different planes prevents oblique measurements and helps distinguish wall thickening from an intracavitary lesion.

Transesophageal echocardiography, when needed, more clearly defines the fossa ovalis, superior septal region, caval opening and atrial relationships. The bicaval view is particularly useful for mapping the distribution; three-dimensional imaging can provide an additional anatomical depiction before a procedure. Echogenicity, however, does not identify adipose composition as specifically as CT and MRI. This modality is therefore chosen when it can resolve an anatomical or functional uncertainty, not as an obligatory step after every already-characteristic CT examination.

CT identifies tissue with generally homogeneous fat attenuation in the septal region and atrial folds. Sparing of the fossa ovalis often leaves two thicker portions on either side. This combination of composition and distribution is far more persuasive than simply exceeding a thickness threshold. Approximately 20 mm is frequently used in the literature as a reference for significant thickening, but no single threshold can replace morphological recognition and clinical assessment.
Multiplanar reconstructions allow the extent to be measured and any caval or atrial compression to be assessed. If CT was performed for another reason, the protocol may suffice to recognize fat but be less suitable for quantifying a hemodynamic consequence, which should be assessed with targeted testing.

MRI confirms the tissue composition by showing a signal similar to that of fat, which decreases on fat-suppression sequences. Cine images document the relationship with filling and the cardiac chambers, while anatomical acquisitions delineate margins and continuity with neighboring deposits. A typical appearance does not show the behavior of a vascularized solid mass. Any thin muscular or fibrous components must be interpreted in context, avoiding treating every minor heterogeneity as grounds for oncological suspicion.

A particular issue is possible FDG uptake on PET studies, also related to the metabolically active adipose component. In a patient undergoing cancer staging, this activity can mimic a neoplastic site. Correct interpretation requires correlation of the metabolic signal with the CT component: distribution within the septal region, fat attenuation and sparing of the fossa ovalis support a lipomatous diagnosis. An uptake value alone cannot reliably distinguish benign from malignant disease.
PET is not routinely requested to diagnose this condition. If the FDG-avid area includes an atypical solid component or does not match the expected configuration, the finding must be investigated further rather than automatically attributed to brown fat.

A lipoma tends to be a well-defined, encapsulated mass that need not spare the fossa ovalis. By contrast, a cardiac myxoma often arises close to the fossa itself and projects into the chamber, with a different attachment and mobility; its matrix does not behave like fat on dedicated sequences. Atrial thrombi, infiltrating neoplasms and metastatic lesions are differentiated by location, relationship to the wall, composition and clinical context. An image showing a mass in the interatrial region is therefore a starting point, not a diagnosis.

Suspicion of a different lesion increases when there are predominant nonadipose components, solid nodules, destruction of structures or an inconsistent course. Comparison with previous examinations is useful, but should be performed in comparable planes. Even a typical finding can coexist with another disorder: in a patient with cancer, not every thoracic abnormality necessarily belongs to the same process, and in a patient with stroke, septal fat does not exclude atrial thrombosis or another embolic source.

In characteristic cases, diagnosis rests on agreement between anatomy and fat characterization. There is no specific laboratory test or universally adopted system of formal clinical criteria. Histology is available when tissue is removed for a genuine indication or at autopsy; it is not routinely required to confirm typical imaging findings. Biopsy is considered only if a significant uncertainty persists that would change management, after weighing the risk and the possibility of resolving the question through imaging review.

Functional assessment and implications for transseptal procedures

Once characterization is complete, any consequences requiring treatment are assessed. An electrocardiogram documents rhythm and conduction; ambulatory monitoring is selected when symptoms are intermittent or an arrhythmia is suspected. Its duration depends on how often episodes occur. Assessment of atrial fibrillation includes associated heart diseases and modifiable factors according to the arrhythmia-specific pathway, rather than attributing everything to the fatty septum.

Suspected venous obstruction requires demonstration of its location and severity. Doppler echocardiography and cross-sectional imaging may document narrowing and its relationship to the right atrium; invasive investigations, if any, are reserved for unresolved questions or treatment planning. A typical asymptomatic finding does not require a systematic search for metastases or family screening. Additional investigations must address a plausible consequence or genuine diagnostic uncertainty.

The condition is particularly relevant before transseptal procedures, such as some electrophysiological or structural interventions. Thickening of the surrounding tissues can make it less intuitive to identify the thin region of the fossa ovalis and alter the perceived resistance during crossing. The operator must have access to an anatomical map, with transesophageal or intracardiac echocardiographic guidance according to the procedure and the center's experience. Lipomatous hypertrophy is not in itself an absolute contraindication, but requires careful planning.
The aim is to identify the anatomical target correctly and its relationships with adjacent structures, without assuming that all visible tissue forms a uniform septum. This distinction is also important when assessing devices or the effects of previous interventions.

Treatment, prognosis and follow-up

The most common approach is conservative management. A reliable diagnosis is documented clearly, explaining the nature of the finding and making images available for future comparisons. In the absence of attributable symptoms, obstruction or diagnostic uncertainty, resection offers no demonstrated benefit. The need for serial surveillance also depends on circumstances: a typical, stable deposit without consequences does not automatically require intensive lifelong imaging.

Atrial fibrillation and other arrhythmias are treated according to their own indications, with symptom control and rate or rhythm management when appropriate. Decisions about anticoagulation depend on the thromboembolic risk associated with the arrhythmia and the patient's circumstances, not on septal fat thickness. Treating hypertension, obesity, sleep apnea and other comorbidities can improve the cardiovascular and arrhythmic profile; however, correcting them must not be presented as a treatment that will certainly eliminate the septal lesion.

Surgery is exceptional and is considered primarily when hemodynamically significant obstruction has been demonstrated. In some presentations involving severe refractory arrhythmias, a surgical strategy may be discussed, but the causal link requires particularly careful assessment and the benefit for rhythm remains uncertain. Resection may require reconstruction of the septum or adjacent tissues: the indication must therefore justify the risk of damaging structures that function adequately in most affected individuals.

Antineoplastic therapies have no role in the typical form, and no specific drug has established efficacy in reducing the accumulation. Prognosis depends predominantly on associated cardiac and other conditions; it is generally favorable when complications are absent. The condition has no demonstrated natural history of malignant transformation. If an atypical appearance develops during surveillance, the appropriate step is to reassess the diagnosis and anatomical comparison, rather than assume that a known deposit has inevitably transformed into a tumor.

Follow-up is agreed upon according to initial uncertainty, symptoms, extent and any planned procedures. The onset of new palpitations, syncope, signs of superior venous congestion or unexplained dyspnea calls for targeted reassessment. When comparing dimensions, use of the same imaging modality and equivalent planes is preferable. In patients undergoing transseptal interventions, documenting the finding remains valuable even when no direct treatment of lipomatous hypertrophy is needed.

Complications and risks of misinterpretation

The most clinically relevant complications are arrhythmias and rare caval or atrial obstruction. Their presence must be documented because the statistical association between septal fat and rhythm disturbances does not justify a causal explanation in every case. Extreme events described in individual reports do not establish a high risk for all patients with an incidental finding. Size becomes important when it affects functional anatomy, procedural access or diagnostic confidence.

A substantial part of the risk arises from misclassification. PET uptake interpreted without the CT component may lead to incorrect cancer staging; an incomplete echocardiographic image may prompt surgery for a presumed neoplasm. Biopsy and resection add risks when performed without a necessary diagnostic or therapeutic question. Conversely, labeling a mass with atypical solid components as lipomatous hypertrophy may delay a different diagnosis. The solution is agreement between tissue, shape and location, with explicit identification of features that do not fit the expected pattern.

During transseptal procedures, inaccurate anatomical interpretation can lead to an inappropriate passage through the tissues, potentially causing wall injury or bleeding. Prior recognition of the spared fossa ovalis and surrounding deposits reduces this risk. Thus, the lesion may be clinically silent yet important for procedural safety: its presence should remain part of the cardiology record even when the final approach is simply conservative.

References
  1. Heyer CM et al. Lipomatous hypertrophy of the interatrial septum: a prospective study of incidence, imaging findings, and clinical symptoms. Chest. 2003;124(6):2068-2073.
  2. Meaney JF et al. CT appearance of lipomatous hypertrophy of the interatrial septum. AJR American Journal of Roentgenology. 1997;168(4):1081-1084.
  3. Laura DM et al. Lipomatous Atrial Septal Hypertrophy: A Review of Its Anatomy, Pathophysiology, Multimodality Imaging, and Relevance to Percutaneous Interventions. Journal of the American Society of Echocardiography. 2016;29(8):717-723.
  4. Nadra I et al. Lipomatous hypertrophy of the interatrial septum: a commonly misdiagnosed mass often leading to unnecessary cardiac surgery. Heart. 2004;90(12):e66.
  5. Xanthopoulos A et al. Lipomatous Hypertrophy of the Interatrial Septum: A Case Report and Review of the Literature. CASE. 2017;1(5):182-189.
  6. Bois MC et al. Benign lipomatous masses of the heart: a comprehensive series of 47 cases with cytogenetic evaluation. Human Pathology. 2014;45(9):1859-1865.
  7. Pruente R et al. Fatty lesions in and around the heart: a pictorial review. British Journal of Radiology. 2015;88(1051):20150157.
  8. Angeli F et al. Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2024;6(6):847-862.
  9. Tyebally S et al. Cardiac Tumors: JACC CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2020;2(2):293-311.
  10. Basso C et al. Cardiac masses and tumours. Heart. 2016;102(15):1230-1245.
  11. Van Gelder IC et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2024;45(36):3314-3414.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.